Michael J. Sayegh

Michael J. Sayegh

Auto-generated profile, based on publicly available information

Michael J. Sayegh

Northwell New Hyde Park New York U.S.A.

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2022 in Journal of Clinical Densitometry
Verified
Journal Article
Closed access
BTBasel M. Touban
Basel M. Touban
MSMichael J. Sayegh
Michael J. Sayegh
JGJesse Galina
Jesse Galina
SPSonja Pavlesen
Sonja Pavlesen
TRTariq Radwan
Tariq Radwan
MAMark Anders
Mark Anders

25 March 2020 in Journal of Orthopaedics
Verified
Journal Article
Closed access
MSMichael J. Sayegh
Michael J. Sayegh
RNRyan A. Nixon
Ryan A. Nixon
DPDean C. Perfetti
Dean C. Perfetti
SRSteven E. Rokito
Steven E. Rokito
NSNicholas A. Sgaglione
Nicholas A. Sgaglione

1 January 2021 in JBJS Case Connector
Verified
Journal Article
Closed access
MSMichael J. Sayegh
Michael J. Sayegh
CLChristopher G. Larsen
Christopher G. Larsen
CPCamille Pinpin
Camille Pinpin
JIJessica M. Intravia
Jessica M. Intravia
KNKate W. Nellans
Kate W. Nellans
Case: We describe a preliminary report of 3 cases of ulnar neuropathy after coronavirus disease 2019 (COVID-19) infection and treatment with intermittent prone positioning. Conclusion: Ulnar neuropathy may be associated with recent COVID-19 infection. The natural process of the disease and intermittent prone positioning are likely risk factors contributing to this finding. Conservative management seems to lead to improvement of symptoms.

31 December 2022 in The Journal of Knee Surgery
Verified
Journal Article
Closed access
PDF file
MSMichael J. Sayegh
Michael J. Sayegh
LGLuke J. Garbarino
Luke J. Garbarino
PGPeter A. Gold
Peter A. Gold
HAHiba K. Anis
Hiba K. Anis
ZCZhongming Chen
Zhongming Chen
MMMichael A. Mont
Michael A. Mont
Given the current healthcare economic environment, substantial efforts have been made to help streamline the in-hospital care for total knee arthroplasty (TKA) patients. While potential cost-reducing factors have been identified in the literature, analyses specifically considering post-anesthesia care unit (PACU) lengths of stay (LOS) are lacking. Therefore, the purpose of this study was to identify factors associated with (1) longer PACU LOS as well as (2) longer Hospital LOS. Prospectively collected TKA data from seven participating hospitals within a large health system were evaluated for patient demographics, body mass indices, Charlson Comorbidity Indices (CCI), surgeon volumes/training, admission types, anesthesia types, PACU LOS, and overall hospital LOS. Complete data was available for 1,690 patients (1,082 females, mean age: 67 years). Univariate and multivariate analytical models were constructed to identify which factors were predictive of longer PACU and overall hospital LOS. Same-day admissions, higher volume surgeons (≥ 100 cases per year), fellowship-trained arthroplasty surgeons, and longer operative times were associated with longer PACU LOS (p < 0.05). Multivariate analyses found age more than or equal to 65 years (β= 0.124) and CCI more than or equal to 3 (β= 0.088) to be associated with longer hospital LOS (p < 0.001). Operative times, PACU LOS, and procedure times (operative time plus PACU LOS) were not associated with longer hospital LOS (p > 0.05). These data identify associative factors for PACU LOS, as well as the influence of time spent in the PACU on overall hospital LOS. Interestingly, this analysis revealed that patients of arthroplasty fellowship-trained and higher-volume surgeons had longer PACU LOS; however, this could be explained by the observation that these particular surgeons tend to perform more complex deformity cases. Also of importance, increased PACU LOS, meaning the patient spent more time in a high-monitored setting immediately after surgery, did not necessarily confer a longer overall hospital LOS. Based on these data, it may be more beneficial to identify alternate sources than time spent in the operating room or PACU to potentially help reduce overall hospital LOS. Level of Evidence II, prospective cohort

1 April 2024 in JBJS Case Connector
Verified
Journal Article
Closed access
MSMichael J. Sayegh
Michael J. Sayegh
JKJoshua M. Keefer
Joshua M. Keefer
ZLZhongyu Li
Zhongyu Li
O it. The nerve was mobilized from the artery with fascial releases. The patient had symptom resolution postoperatively. Conclusion: To our knowledge, this cause of compression has not been described before and should be considered in a differential diagnosis. In addition, clinicians should be aware of this anatomical variant during venipunctures and surgical approaches....

22 February 2022 in HAND
Verified
Journal Article
Closed access
MSMichael J. Sayegh
Michael J. Sayegh
CPCamille Pinpin
Camille Pinpin
CLChristopher G. Larsen
Christopher G. Larsen
ENEric V. Neufeld
Eric V. Neufeld
JIJessica M. Intravia
Jessica M. Intravia
DGDaniel Grande
Daniel Grande
Background: It is common practice for hand surgeons to premix corticosteroids with a local anesthetic and store the mixture in pre-loaded syringes for rapid use during clinic. However, any possible loss of efficacy with this practice has never been studied. The purpose of this study, therefore, is to determine whether premixing betamethasone sodium phosphate/betamethasone acetate (BSP) and lidocaine (L) at different time intervals from injection has diminishing anti-inflammatory effects on chondrocytes in vitro. Methods: Human articular chondrocytes were partitioned into six groups: two controls and four experimental conditions. The negative control had growth media only. The positive control had growth media and inflammatory cytokines (interleukin-1β and oncostatin M). Experimental conditions were additionally treated with BSP alone or BSP mixed with lidocaine (BSP + L) at the time of treatment (0 hours), or at 4 or 24 hours prior. Relative expressions of inflammatory genes were measured. Results: Relative to the positive control, chondrocytes in all experimental conditions decreased expression of TNF-α, MMP-3, and ADAMTS-4. Chondrocytes exposed to BSP only or BSP + L at 4 hours or 24 hours prior to treatment decreased expression of IL-8. Chondrocytes exposed to BSP only or BSP + L at 0 hours or 4 hours prior to treatment decreased expression of MMP-1. There were no significant differences in expression of IL-6 or MMP-13. Conclusions: Treatment with BSP + L prepared in pre-loaded syringes at varying time intervals up to 24 hours prior to injection does not significantly impact the ability of the mixture to reduce expression of certain key inflammatory mediators in vitro.